Impact of fenofibrate on NAFLD/NASH: A genetic perspective
Highlights•NAFLD is highly prevalent and affects at least one-third of the global
population.•Currently, there is no drug to cure NAFLD.•Fenofibrate is a PPARα agonist with …
population.•Currently, there is no drug to cure NAFLD.•Fenofibrate is a PPARα agonist with …
Epigenetics in NAFLD/NASH: Targets and therapy
Recently non-alcoholic fatty liver disease (NAFLD) has grabbed considerable scientific
attention, owing to its rapid increase in prevalence worldwide and growing burden on end …
attention, owing to its rapid increase in prevalence worldwide and growing burden on end …
Liver protective effect of fenofibrate in NASH/NAFLD animal models
Nonalcoholic fatty liver disease (NAFLD) is initiated by excessive fat buildup in the liver,
affecting around 35% of the world population. Various circumstances contribute to the …
affecting around 35% of the world population. Various circumstances contribute to the …
Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD)
JA Del Campo, R Gallego-Durán, P Gallego… - International journal of …, 2018 - mdpi.com
Genetics and epigenetics play a key role in the development of several diseases, including
nonalcoholic fatty liver disease (NAFLD). Family studies demonstrate that first degree …
nonalcoholic fatty liver disease (NAFLD). Family studies demonstrate that first degree …
[HTML][HTML] Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease
MS Kostapanos, A Kei, MS Elisaf - World journal of hepatology, 2013 - ncbi.nlm.nih.gov
Non-alcoholic fatty liver disease (NAFLD) is a common health problem with a high mortality
burden due to its liver-and vascular-specific complications. It is associated with obesity, high …
burden due to its liver-and vascular-specific complications. It is associated with obesity, high …
Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies
YA Lee, SL Friedman - Journal of internal medicine, 2022 - Wiley Online Library
Non‐alcoholic fatty liver disease is comprised of either simple steatosis (non‐alcoholic fatty
liver) or a more advanced inflammatory and fibrogenic stage (non‐alcoholic steatohepatitis …
liver) or a more advanced inflammatory and fibrogenic stage (non‐alcoholic steatohepatitis …
[HTML][HTML] Molecular interactions between NAFLD and xenobiotic metabolism
Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic
syndrome, is a complex multifactorial disease characterized by metabolic deregulations that …
syndrome, is a complex multifactorial disease characterized by metabolic deregulations that …
Evolving role for pharmacotherapy in NAFLD/NASH
SL Attia, S Softic, M Mouzaki - Clinical and translational science, 2021 - Wiley Online Library
Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent, dynamic disease that occurs
across the age spectrum and can lead to cirrhosis and hepatocellular carcinoma. There are …
across the age spectrum and can lead to cirrhosis and hepatocellular carcinoma. There are …
NAFLD: mechanisms, treatments, and biomarkers
F Nassir - Biomolecules, 2022 - mdpi.com
Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic-associated fatty liver
disease (MAFLD), is one of the most common causes of liver diseases worldwide. NAFLD is …
disease (MAFLD), is one of the most common causes of liver diseases worldwide. NAFLD is …
[HTML][HTML] Metabolic targets in nonalcoholic fatty liver disease
WP Esler, KK Bence - Cellular and molecular gastroenterology and …, 2019 - Elsevier
The prevalence and diagnosis of nonalcoholic fatty liver disease (NAFLD) is on the rise
worldwide and currently has no FDA-approved pharmacotherapy. The increase in disease …
worldwide and currently has no FDA-approved pharmacotherapy. The increase in disease …